Topical administration of novel FKBP12 ligand MP-004 improves retinal function and structure in retinitis pigmentosa models
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Purpose
This study evaluates the therapeutic potential of MP-004, a novel FKBP12 ligand, in the treatment of inherited retinal dystrophies (IRDs). MP-004 targets FKBP12/RyR interaction, which is disrupted in several neurological disorders with underlying oxidative stress.
Methods
The toxicity and efficacy of MP-004 were examined in vitro in 661W cells. Efficacy was evaluated in phototoxic and H 2 O 2 -induced damage using impedance assays, calcium igaing and in situ PLA. In vivo, MP-004 efficacy was evaluated in the rd10 mouse model of retinitis pigmenetosa (RP) by topical ocular instillation. Retinal function was assessed by electroretinography (ERG), visual acuity was measured using a water maze test, and retinal structure was analyzed morphometrically.
Results
MP-004 exhibited low toxicity (LD 50 : 1.22 mM) and effectively protected 661W cells from phototoxicity (EC 50 : 30.6 nM). Under oxidative stress conditions, MP-004 preserved FKBP12.6/RyR2 interaction, partially restored endoplasmic reticulum calcium stores and prevented cell death. In vivo, MP-004 significantly preserved retinal function in rd10 mice, with ERG wave amplitude increases of up to 50% in scotopic and 71% in photopic conditions, corresponding to rod and cone functions, respectively. Additionally, MP-004 improved visual acuity for low spatial frequency patterns, and preserved retinal structure with a 23% increase in outer nuclear layer thickness, and preservation in the number of rods and cones and their segment length.
Conclusions
MP-004 shows promise as a therapeutic agent for RP, preserving retinal structure and function, likely through modulation of FKBP12.6/RyR2 interaction. Further studies are needed to explore its pharmacokinetics and efficacy in other IRD models.
